IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.
DTC
IGF2
RAI refractoriness
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
05
02
2021
accepted:
12
04
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Differentiated thyroid cancer (DTC) is the most frequent endocrine tumor with a good prognosis after primary treatment in most cases. By contrast, 30-40% of patients with metastatic DTC are unresponsive to
Identifiants
pubmed: 34149901
doi: 10.3892/ol.2021.12851
pii: OL-0-0-12851
pmc: PMC8200939
doi:
Types de publication
Journal Article
Langues
eng
Pagination
590Informations de copyright
Copyright: © Crezee et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Endocr Relat Cancer. 2019 Jan 1;26(1):197-214
pubmed: 30121624
Oncotarget. 2017 Jul 18;8(29):47269-47283
pubmed: 28521298
Ann Oncol. 2012 Oct;23 Suppl 7:vii110-9
pubmed: 22997443
Biomarkers. 2011 Jun;16(4):346-54
pubmed: 21506705
Int J Mol Sci. 2019 Oct 03;20(19):
pubmed: 31623387
Cancer Med. 2018 Mar;7(3):616-625
pubmed: 29455465
Oncotarget. 2016 Apr 5;7(14):18346-55
pubmed: 26943032
Mol Cancer Res. 2020 Apr;18(4):549-559
pubmed: 31941753
Front Endocrinol (Lausanne). 2011 Dec 06;2:93
pubmed: 22654833
Oncogene. 2017 Sep 21;36(38):5341-5355
pubmed: 28534511
Cancer Res. 2014 Nov 15;74(22):6531-41
pubmed: 25273088
Oncogene. 1999 Apr 15;18(15):2471-9
pubmed: 10229198
Thyroid. 2020 May;30(5):732-738
pubmed: 31910091
Front Endocrinol (Lausanne). 2015 May 15;6:77
pubmed: 26029167
Endocr Relat Cancer. 2013 Jan 07;20(1):R1-R17
pubmed: 23207292
Int J Mol Sci. 2018 Nov 30;19(12):
pubmed: 30513575
Eur J Cancer. 2018 Mar;92:40-47
pubmed: 29413688
Mod Pathol. 2009 Jul;22(7):914-21
pubmed: 19407853
Oncol Rep. 2018 Dec;40(6):3359-3369
pubmed: 30272326
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
EJNMMI Res. 2019 Oct 15;9(1):93
pubmed: 31617002
Future Med Chem. 2009 Sep;1(6):1153-71
pubmed: 21425998
N Engl J Med. 2016 Sep 15;375(11):1054-67
pubmed: 27626519
J Clin Endocrinol Metab. 2011 Mar;96(3):766-74
pubmed: 21123448
Clin Chem Lab Med. 2019 Dec 18;58(1):130-137
pubmed: 31444962
J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
pubmed: 16684830
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
Clin Cancer Res. 2015 Feb 15;21(4):701-11
pubmed: 25212606
J Surg Oncol. 2014 Sep;110(4):375-82
pubmed: 24961938
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Mol Cancer Ther. 2017 Oct;16(10):2223-2233
pubmed: 28729397
PLoS One. 2019 Jun 28;14(6):e0219155
pubmed: 31251794
J Clin Endocrinol Metab. 2002 Jan;87(1):245-54
pubmed: 11788654
PLoS One. 2017 Jul 13;12(7):e0179664
pubmed: 28704384
Mol Cell Biol. 1999 May;19(5):3278-88
pubmed: 10207053
J Mol Diagn. 2016 Nov;18(6):851-863
pubmed: 27637301
Cytokine Growth Factor Rev. 2015 Jun;26(3):371-7
pubmed: 25704323
Clin Colorectal Cancer. 2010 Oct;9(4):219-23
pubmed: 20920993
Endocr Relat Cancer. 2013 Oct 24;20(6):R321-39
pubmed: 24080445
Virchows Arch. 2003 Aug;443(2):139-45
pubmed: 12845531
Mol Biol Rep. 2019 Aug;46(4):4201-4212
pubmed: 31147861
J Clin Oncol. 2014 Sep 1;32(25):2718-26
pubmed: 25024077
Cancer Sci. 2018 Apr;109(4):944-955
pubmed: 29383798
EBioMedicine. 2017 Mar;17:45-56
pubmed: 28258923
Mol Cancer Ther. 2010 Oct;9(10):2652-64
pubmed: 20924128
Thyroid. 2017 Jun;27(6):751-756
pubmed: 28463585
Oncogene. 2017 Mar 2;36(9):1276-1286
pubmed: 27546618
Eur J Endocrinol. 2015 Sep;173(3):399-408
pubmed: 26104753